Max GLP-1

Glucagon-like peptide-1 (GLP-1) is an incretin hormone widely recognized for its role in enhancing insulin secretion and improving glycemic control. Beyond its antidiabetic effects, emerging evidence suggests that GLP-1 may influence renal physiology, hematological and glucose levels. This study investigates the subacute toxicity effects of MaxGLP-1 a novel analogue of GLP-1 administration on the kidney, hematological and blood glucose levels in experimental models over a 28 day period. A total of 20 rats were divided into four groups and were fed and given water daily. Group 1 was the control and was exposed to standard feeding and water only, Group 2 was administered 10mg/kg of MaxGLP-1, Group 3 was administered 60mg/kg MaxGLP-1 drug while Group 3 was administered 600mg/kg doses of MaxGLP-1. At the end of the study, animals were sacrificed, the kidneys were harvested and taken to the laboratory to be examined, blood samples were also collected and centrifuged to obtain the serum and were subjected to biochemical assays. Findings showed dose-related changes in serum creatinine and urea, indicating possible renal stress. Haematological analysis revealed mild but notable shifts in erythrocyte and leukocyte indices, while glucose levels decreased significantly across treatment groups. Overall, Max GLP- 1 exhibited hypoglycaemic effects with minimal haematological disturbances, though higher doses suggested early signs of renal compromise. These results highlight the need for cautious dose optimization and further investigation into long-term safety

This study evaluated the proximate composition and in vitro antioxidant capacity of Max GLP-1, a nutraceutical supplement marketed for enhancing Glucagon-Like Peptide-1 activity, improving glucose control, and regulating appetite. The product is formulated with sorghum polyphenols, citrus flavonoids, and postbiotic compounds. Despite its increasing consumer use, limited scientific evidence exists regarding its nutritional and biochemical properties. Proximate composition, including moisture, ash, crude protein, crude fat, crude fiber, and carbohydrate content, was determined using standard Association of Official Analytical Chemists methods. Antioxidant activity was assessed using the DPPH Radical Scavenging Assay and Ferric Reducing Antioxidant Power techniques.

Results from the proximate analysis revealed that Max GLP-1 is predominantly carbohydrate-based (53.84%) with high moisture content (42.74%), while containing very low levels of crude protein (1.42%), crude fiber (0.42%), crude fat (0.01%), and ash (1.57%). These findings indicate a low nutrient density and suggest that the product’s functional properties are primarily derived from phytochemicals rather than macronutrients. Antioxidant evaluation showed moderate activity, with 44.61% DPPH radical inhibition and 41.56% FRAP reducing capacity, compared with the significantly higher antioxidant activity of the reference standard Ascorbic Acid, which recorded 95.44% and 89.25% respectively.

The findings confirm the presence of moderately active antioxidant compounds such as polyphenols and flavonoids within the supplement. However, the study does not provide sufficient evidence to support claims related to GLP-1 enhancement, weight regulation, or metabolic benefits. Further investigations involving phytochemical quantification, bioactivity profiling, and clinical trials are recommended to validate the broader health claims associated with Max GLP-1.